Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2021

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.
Epistemonikos ID: 3361665bcb09f8b120f0f218749188f9daef2fbf
First added on: May 09, 2024